Anti PD-1 antibodies, either as monotherapy or in combination with anti-CTLA-4 ones, should be considered first-line treatment for all patients with unresectable metastatic melanoma and independent of tumor BRAF mutational status [32,33,34]. This evidence concerns the gene BRAF and metastatic melanoma.